Cahill Represents Initial Purchasers in Acquisition Financing for Mallinckrodt Pharmaceuticals
Date: 04/15/15
Cahill represented the joint book-running managers in connection with the Rule 144A offering of $1,400,000,000 of Senior Notes, comprised of $700,000,000 aggregate principal amount of 4.875% Senior Notes due 2020, and $700,000,000 aggregate principal amount of 5.500% Senior Notes due 2025 by Mallinckrodt Pharmaceuticals, a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and medical imaging agents. Proceeds from the offering will be used in connection with Mallinckrodt’s proposed acquisition of Ikaria Inc., a fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed for the critical care market.